{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-067651","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.140020+00:00","generated_at":"2026-06-01T06:48:39.493880+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer","bullets":["44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.","No DLTs or grade 4/5 AEs observed to date; single grade 1 neuropathy (resolved) and 3 skin rashes (resolved).","Free MMAE levels lower than enfortumab vedotin across all doses up to 4.5 mg/Kg.","Enrollment expanded to 37 patients (25 evaluable); US phase 1 completing Q4 2024, data Q1 2025.","Preventative eye measures introduced after two grade 3 corneal disorders; no further cases at 4.5 mg/Kg."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-067651","json":"https://secwatch.observer/filing/0000950170-24-067651.json","markdown":"https://secwatch.observer/filing/0000950170-24-067651.md","text":"https://secwatch.observer/filing/0000950170-24-067651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/0000950170-24-067651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/crbp-20240601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:48:39.493880+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}